Blood Endothelial-Cell Extracellular Vesicles as Potential Biomarkers for the Selection of Plasma in COVID-19 Convalescent Plasma Therapy
Open Access
Abstract
Despite the advancement of vaccination and therapies currently available, deaths due to the coronavirus disease 2019 (COVID-19) are still heavily documented. Severely infected individuals experience a generalized inflammatory storm, caused by massive secretion of pro-inflammatory cytokines that can lead to endothelial dysfunction, cardiovascular disease, multi-organ failure, and even death. COVID-19 convalescent plasma (CCP) therapy, selected primarily based on anti-SARS-CoV-2 antibody levels, has not been as convincing as expected in the fight against COVID-19. Given the consequences of a dysfunctional endothelium on the progression of the disease, we propose that the selection of plasma for CCP therapy should be based on more specific parameters that take into consideration the effect on vascular inflammation. Thus, in the present study, we have characterized a subset of CCP that have been used for CCP therapy and measured their anti- or pro-inflammatory effect on human coronary artery endothelial cells (HCAECs). Our data revealed that the longer the time lapse between the onset of symptoms and the plasma donation, the more mitochondrial dysfunction can be evidenced. The concentration of blood endothelial cell extracellular vesicles (BEC-EVs) was increased in the plasma of young individuals with mild symptoms. This type of selected convalescent plasma promoted the activation of the blood vascular endothelium, as reflected by the overexpression of ICAM1 and NFκB1 and the downregulation of VE-Cadherin. We propose this mechanism is a warning signal sent by the injured endothelium to trigger self-defense of peripheral blood vessels against excessive inflammation. Therefore, these results are in line with our previous data. They suggest that a more specific selection of COVID-19 convalescent plasma should be based on the time of donation following the onset of the clinical symptoms of the donor, the severity of the symptoms, and the age of the donor. These characteristics are relatively easy to identify in any hospital and would reflect the concentration of plasma BEC-EVs and be optimal in CCP therapy.Keywords
Funding Information
- Canadian Institutes of Health Research (950-232250)
- Fondation Institut de Cardiologie de Montréal
This publication has 33 references indexed in Scilit:
- Tips and tricks for flow cytometry-based analysis and counting of microparticlesTransfusion and Apheresis Science, 2015
- Programmed cell death and its role in inflammationMilitary Medical Research, 2015
- Blockade of VEGF Receptor-3 Aggravates Inflammatory Bowel Disease and Lymphatic Vessel EnlargementInflammatory Bowel Diseases, 2013
- Mitochondrial Complex III Deficiency Caused by a HomozygousUQCRC2Mutation Presenting with Neonatal-Onset Recurrent Metabolic DecompensationHuman Mutation, 2013
- Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Insight from a substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trialAmerican Heart Journal, 2012
- An overview of lymphatic vessels and their emerging role in cardiovascular diseaseJournal of Cardiovascular Disease Research, 2011
- NDUFA2 Complex I Mutation Leads to Leigh DiseaseThe American Journal of Human Genetics, 2008
- The genetics and pathology of oxidative phosphorylationNature Reviews Genetics, 2001
- Polymorphonuclear leukocyte adhesion triggers the disorganization of endothelial cell-to-cell adherens junctions.Journal of Cell Biology, 1996
- Leucocyte-endothelial interactions and regulation of leucocyte migrationThe Lancet, 1994